290 related articles for article (PubMed ID: 22689024)
21. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
[TBL] [Abstract][Full Text] [Related]
23. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.
Gould IM; Miró JM; Rybak MJ
Int J Antimicrob Agents; 2013 Sep; 42(3):202-10. PubMed ID: 23845504
[TBL] [Abstract][Full Text] [Related]
24. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
25. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
26. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Alder J
Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
[TBL] [Abstract][Full Text] [Related]
27. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
28. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients.
Sader HS; Fritsche TR; Jones RN
J Chemother; 2008 Oct; 20(5):570-6. PubMed ID: 19028618
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical experience with daptomycin.
Hawkey PM
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
[TBL] [Abstract][Full Text] [Related]
30. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
31. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
32. Daptomycin, a lipopeptide antibiotic in clinical practice.
Weis F; Beiras-Fernandez A; Schelling G
Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
[TBL] [Abstract][Full Text] [Related]
33. [Daptomycin in Gram-positive bacterial infections in oncohematological patients and transplant recipients].
Carratalà J; Len O; de la Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():43-9. PubMed ID: 22541975
[TBL] [Abstract][Full Text] [Related]
34. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
Segreti JA; Crank CW; Finney MS
Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
[TBL] [Abstract][Full Text] [Related]
35. Daptomycin: a new drug class for the treatment of Gram-positive infections.
Alder JD
Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
[TBL] [Abstract][Full Text] [Related]
36. Management of cSSTIs: the role of daptomycin.
Garau J
Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
[TBL] [Abstract][Full Text] [Related]
37. Daptomycin in endocarditis and bacteraemia: a British perspective.
Warren RE
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii25-33. PubMed ID: 18829722
[TBL] [Abstract][Full Text] [Related]
38. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.
Falagas ME; Giannopoulou KP; Ntziora F; Vardakas KZ
J Antimicrob Chemother; 2007 Jul; 60(1):7-19. PubMed ID: 17550889
[TBL] [Abstract][Full Text] [Related]
39. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
[No Abstract] [Full Text] [Related]
40. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
Hair PI; Keam SJ
Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]